In-stent restenosis after percutaneous transluminal angioplasty and stenting (PTAS) due to neointimal hyperplasia is a potential cause of clinical complications, including repeated revascularization and ischemic events. Neointimal hyperplasia induced by an inflammatory response to the stent strut may be a possible mechanism of in-stent restenosis. Intravenous infusion of bone marrow–derived mesenchymal stem cells (MSCs) has been reported to show therapeutic efficacy for cerebral stroke, presumably by an antiinflammatory effect. This study aimed to determine whether MSCs can reduce or prevent neointimal hyperplasia induced by an endovascular stent.
In this study, two types of bare metal stents were deployed using a porcine (mini-pig) model. One stent was implanted in the common carotid artery (CCA), which is considered quite similar to the human CCA, and the other was inserted in the superficial cervical artery (SCA), which is similar in size to the human middle cerebral artery. Angiographic images, intravascular ultrasound (IVUS) imaging, and microscopic images were used for analysis.
Angiographic images and IVUS studies revealed that intravenous infusion of MSCs immediately after deployment of stents prevented in-stent stenosis of the CCA and SCA. Histological analysis also confirmed that inflammatory responses around the stent struts were reduced in both the stented CCA and SCA in the mini-pig.
Intravenous infusion of MSCs inhibited the inflammatory reaction to an implanted stent strut, and prevented progressive neointimal hyperplasia in the stented CCA and SCA in a porcine model. Thus, MSC treatment could attenuate the recurrence of cerebral ischemic events after stenting.
The Neurosurgery Research & Education Foundation (NREF) is celebrating its 40th anniversary this month. Since its inception, the NREF has invested nearly $30 million in the future of neurosurgery through its support of basic science and clinical research, as well as life-long education, to foster improved outcomes for our patients with neurosurgical diseases. See the article by Agarwal et al. (pp 1905–1912).
INCLUDE WHEN CITING Published online October 4, 2019; DOI: 10.3171/2019.7.JNS19575.
Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L: Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013:928315, 2013
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al.: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365:993–1003, 2011
Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ: Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 118:330–338, 2011
de Araújo Farias V, Carrillo-Gálvez AB, Martín F, Anderson P: TGF-β and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev 43:25–37, 2018
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317, 2006
Dumont TM, Natarajan SK, Eller JL, Mocco J, Kelly WH Jr, Snyder KV, et al.: Primary stenting for acute ischemic stroke using the Enterprise vascular reconstruction device: early results. J Neurointerv Surg 6:363–372, 2014
Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al.: Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 26:720–724, 1995
Fields JD, Liu KC, Barnwell SL, Clark WM, Lutsep HL: Indications and applications of arterial stents for stroke prevention in atherosclerotic intracranial stenosis. Curr Cardiol Rep 12:20–28, 2010
Gao P, Zhou Y, Xian L, Li C, Xu T, Plunkett B, et al.: Functional effects of TGF-β1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma. J Immunol 192:4560–4570, 2014
Griessenauer CJ, Foreman P, Deveikis JP, Harrigan MR: Endovascular tools available for the treatment of cerebrovascular disease. Neurosurg Clin N Am 25:387–394, 2014
Gröschel K, Schnaudigel S, Pilgram SM, Wasser K, Kastrup A: A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 40:e340–e347, 2009
Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al.: Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94:1247–1254, 1996
Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, et al.: Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 134:1790–1807, 2011
Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD: A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 1007:1–9, 2004
Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI: Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4:1057–1066, 2011
Iwata T, Mori T, Tajiri H, Miyazaki Y, Nakazaki M: Safety and effectiveness of emergency carotid artery stenting for a high-grade carotid stenosis with intraluminal thrombus under proximal flow control in hyperacute and acute stroke. J Neurointerv Surg 5:40–44, 2013
Jones GT, Kay IP, Chu JW, Wilkins GT, Phillips LV, McCormick M, et al.: Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 26:e121–e125, 2006
Katsaros KM, Kastl SP, Zorn G, Maurer G, Wojta J, Huber K, et al.: Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv 3:90–97, 2010
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG: Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160:1577–1579, 2010
Kim S, Honmou O, Kato K, Nonaka T, Houkin K, Hamada H, et al.: Neural differentiation potential of peripheral blood- and bone-marrow-derived precursor cells. Brain Res 1123:27–33, 2006
Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB: In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224–230, 1998
Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Kobune M, Hirai S, et al.: BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther 9:189–197, 2004
Kurre W, Aguilar-Pérez M, Fischer S, Arnold G, Schmid E, Bäzner H, et al.: Solving the issue of restenosis after stenting of intracranial stenoses: experience with two thin-strut drug-eluting stents (DES)-Taxus Element™ and Resolute Integrity™. Cardiovasc Intervent Radiol 38:583–591, 2015
Lankford KL, Arroyo EJ, Nazimek K, Bryniarski K, Askenase PW, Kocsis JD: Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord. PLoS One 13:e0190358, 2018
Lee CW, Lin CC, Lin WN, Liang KC, Luo SF, Wu CB, et al.: TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292:L799–L812, 2007
Liu H, Honmou O, Harada K, Nakamura K, Houkin K, Hamada H, et al.: Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 129:2734–2745, 2006
Liu JP, Wang YZ, Li YK, Cheng Q, Zheng Z: Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting. Neural Regen Res 10:631–635, 2015
Mori M, Sakata K, Nakanishi C, Nakahashi T, Kawashiri MA, Yoshioka K, et al.: Early endothelialization associated with a biolimus A9 bioresorbable polymer stent in a porcine coronary model. Heart Vessels 32:1244–1252, 2017
Morita T, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Oka S, et al.: Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience 335:221–231, 2016
Nagahama H, Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Namioka T, Namioka A, et al.: Preservation of interhemispheric cortical connections through corpus callosum following intravenous infusion of mesenchymal stem cells in a rat model of cerebral infarction. Brain Res 1695:37–44, 2018
Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Namioka T, Namioka A, et al.: Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats. J Neurosurg 127:917–926, 2017
Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Suzuki J, Sasaki Y, et al.: Intravenous infusion of mesenchymal stem cells improves impaired cognitive function in a cerebral small vessel disease model. Neuroscience 408:361–377, 2019
Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R: The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 100 (8B):36M–44M, 2007
Namioka A, Namioka T, Sasaki M, Kataoka-Sasaki Y, Oka S, Nakazaki M, et al.: Intravenous infusion of mesenchymal stem cells for protection against brainstem infarction in a persistent basilar artery occlusion model in the adult rat. J Neurosurg [epub ahead of print October 12, 2018. DOI: 10.3171/2018.4.JNS173121]
Namioka T, Namioka A, Sasaki M, Kataoka-Sasaki Y, Oka S, Nakazaki M, et al.: Intravenous infusion of mesenchymal stem cells promotes functional recovery in a rat model of chronic cerebral infarction. J Neurosurg [epub ahead of print October 26, 2018. DOI: 10.3171/2018.5.JNS18140]
Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD: Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab 28:329–340, 2008
Oshigiri T, Sasaki T, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Oka S, et al.: Intravenous infusion of mesenchymal stem cells alters motor cortex gene expression in a rat model of acute spinal cord injury. J Neurotrauma 36:411–420, 2019
Prockop DJ, Oh JY: Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 20:14–20, 2012
Radtke C, Akiyama Y, Brokaw J, Lankford KL, Wewetzer K, Fodor WL, et al.: Remyelination of the nonhuman primate spinal cord by transplantation of H-transferase transgenic adult pig olfactory ensheathing cells. FASEB J 18:335–337, 2004
Salem MM, Alturki AY, Fusco MR, Thomas AJ, Carter BS, Chen CC, et al.: Carotid artery stenting vs. carotid endarterectomy in the management of carotid artery stenosis: lessons learned from randomized controlled trials. Surg Neurol Int 9:85, 2018
Sasaki M, Honmou O, Akiyama Y, Uede T, Hashi K, Kocsis JD: Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia 35:26–34, 2001
Sasaki M, Honmou O, Kocsis JD: A rat middle cerebral artery occlusion model and intravenous cellular delivery. Methods Mol Biol 549:187–195, 2009
Sasaki M, Honmou O, Radtke C, Kocsis JD: Development of a middle cerebral artery occlusion model in the nonhuman primate and a safety study of i.v. infusion of human mesenchymal stem cells. PLoS One 6:e26577, 2011
Sasaki M, Radtke C, Tan AM, Zhao P, Hamada H, Houkin K, et al.: BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 29:14932–14941, 2009
Sasaki Y, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Suzuki J, et al.: Synergic effects of rehabilitation and intravenous infusion of mesenchymal stem cells after stroke in rats. Phys Ther 96:1791–1798, 2016
Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, et al.: Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 1:143–153, 2008
Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, et al.: Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 14:493–507, 2018
Sorkin GC, Dumont TM, Eller JL, Mokin M, Snyder KV, Levy EI, et al.: Cerebrovascular neurosurgery in evolution: the endovascular paradigm. Neurosurgery 74 (Suppl 1):S191–S197, 2014
St-Pierre Y, Van Themsche C, Estève PO: Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy 2:206–215, 2003
Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al.: Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294:1215–1223, 2005
Turk AS, Levy EI, Albuquerque FC, Pride GL Jr, Woo H, Welch BG, et al.: Influence of patient age and stenosis location on wingspan in-stent restenosis. AJNR Am J Neuroradiol 29:23–27, 2008
Vajda Z, Aguilar M, Göhringer T, Horváth-Rizea D, Bäzner H, Henkes H: Treatment of intracranial atherosclerotic disease with a balloon-expandable paclitaxel eluting stent: procedural safety, efficacy and mid-term patency. Clin Neuroradiol 22:227–233, 2012
Vajda Z, Schmid E, Güthe T, Klötzsch C, Lindner A, Niehaus L, et al.: The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent. Neurosurgery 70:91–101, 2012
van Hout BA, Serruys PW, Lemos PA, van den Brand MJ, van Es GA, Lindeboom WK, et al.: One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 91:507–512, 2005
Virmani R, Kolodgie FD, Farb A, Lafont A: Drug eluting stents: are human and animal studies comparable? Heart 89:133–138, 2003
Wasser K, Schnaudigel S, Wohlfahrt J, Psychogios MN, Knauth M, Gröschel K: Inflammation and in-stent restenosis: the role of serum markers and stent characteristics in carotid artery stenting. PLoS One 6:e22683, 2011
Wu CY, Hsieh HL, Sun CC, Tseng CP, Yang CM: IL-1 beta induces proMMP-9 expression via c-Src-dependent PDGFR/PI3K/Akt/p300 cascade in rat brain astrocytes. J Neurochem 105:1499–1512, 2008
Yuki I, Kan I, Golshan A, Sohn J, Murayama Y, Vinters HV, et al.: A swine model to analyze arterial structural changes induced by mechanical thrombectomy. AJNR Am J Neuroradiol 34:E87–E90, 2013
Zhang R, Jiang F, Chen CS, Wang T, Feng J, Tao T, et al.: Serum levels of IL-1 β, IL-6, TGF- β, and MMP-9 in patients undergoing carotid artery stenting and regulation of MMP-9 in a new in vitro model of THP-1 cells activated by stenting. Mediators Inflamm 2015:956082, 2015
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 956 | 484 | 21 |
Full Text Views | 179 | 82 | 9 |
PDF Downloads | 158 | 90 | 14 |
EPUB Downloads | 0 | 0 | 0 |